WS01.02Use of medications for sleep, depression, and anxiety in people with cystic fibrosis before and after initiation of elexacaftor/tezacaftor/ivacaftor

IF 5.4 2区医学 Q1 RESPIRATORY SYSTEM

Journal of Cystic Fibrosis Pub Date : 2025-06-01 DOI:10.1016/j.jcf.2025.03.493

J.N. Wang , C. Bjørn Jensen , H.K. Råket , M. Frahm Olsen , T. Qvist , D. Faurholt-Jepsen , J. Petersen , E. Jimenez-Solem , TransformCF Study Group

{"title":"WS01.02Use of medications for sleep, depression, and anxiety in people with cystic fibrosis before and after initiation of elexacaftor/tezacaftor/ivacaftor","authors":"J.N. Wang , C. Bjørn Jensen , H.K. Råket , M. Frahm Olsen , T. Qvist , D. Faurholt-Jepsen , J. Petersen , E. Jimenez-Solem , TransformCF Study Group","doi":"10.1016/j.jcf.2025.03.493","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>Investigate the association between initiation of elexacaftor/tezacaftor/ivacaftor (ETI) and the use of medications for sleep, depression, and anxiety in people with cystic fibrosis (pwCF).</div></div><div><h3>Methods</h3><div>All pwCF aged ≥12 years initiating ETI treatment 21.08.2020-31.12.2021 in Denmark were included in a pre-post study with two years of follow-up in both the pre- and post-intervention periods. A control group from the general population was matched 1:10 on age and sex. Outcomes were prevalent user status defined as at least one redeemed prescription in the preceding year of 1) sleep-promoting medicines (SPM) and 2) antidepressants and/or anxiolytics (AA). Prescriptions were obtained from the Danish National Prescription Registry, which records all redeemed prescriptions regardless of the prescribing physician. Odds ratios (ORs) for the outcome was derived from generalized linear mixed models adjusted for age and days of COVID lockdown.</div></div><div><h3>Results</h3><div>286 pwCF were included in the study. In the year prior to ETI initiation, 5.2% of pwCF were prevalent users of SPM, increasing to 9.0% at the second year after ETI initiation. Conversely, pwCF using AA increased from 4.9% to 8.1%.</div><div>The adjusted ORs for being a prevalent user of SPM at year 2 compared to the pre-ETI period was 10.9 (95% CI 2.1-55.2; p=0.004) for pwCF, and this increase in odds at year 2 was significantly higher (p=0.014) in pwCF than in controls.</div><div>The adjusted ORs for being a prevalent user of AA at year 2 compared to the pre-ETI period was 11.9 (95% CI 1.8-77.0; p=0.009) for pwCF. However, this effect was not significantly different in pwCF than in controls (p=0.090).</div></div><div><h3>Conclusion</h3><div>We found an increase in use of SPM in pwCF after ETI initiation that was significantly higher than in the background population, strengthening the suspicion of a causal relationship between ETI and sleep disturbances. We also found an increase in use of AA in pwCF, but a similar increase was seen in the background population.</div></div>","PeriodicalId":15452,"journal":{"name":"Journal of Cystic Fibrosis","volume":"24 ","pages":"Page S1"},"PeriodicalIF":5.4000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cystic Fibrosis","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1569199325005892","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

Investigate the association between initiation of elexacaftor/tezacaftor/ivacaftor (ETI) and the use of medications for sleep, depression, and anxiety in people with cystic fibrosis (pwCF).

Methods

All pwCF aged ≥12 years initiating ETI treatment 21.08.2020-31.12.2021 in Denmark were included in a pre-post study with two years of follow-up in both the pre- and post-intervention periods. A control group from the general population was matched 1:10 on age and sex. Outcomes were prevalent user status defined as at least one redeemed prescription in the preceding year of 1) sleep-promoting medicines (SPM) and 2) antidepressants and/or anxiolytics (AA). Prescriptions were obtained from the Danish National Prescription Registry, which records all redeemed prescriptions regardless of the prescribing physician. Odds ratios (ORs) for the outcome was derived from generalized linear mixed models adjusted for age and days of COVID lockdown.

Results

286 pwCF were included in the study. In the year prior to ETI initiation, 5.2% of pwCF were prevalent users of SPM, increasing to 9.0% at the second year after ETI initiation. Conversely, pwCF using AA increased from 4.9% to 8.1%.

The adjusted ORs for being a prevalent user of SPM at year 2 compared to the pre-ETI period was 10.9 (95% CI 2.1-55.2; p=0.004) for pwCF, and this increase in odds at year 2 was significantly higher (p=0.014) in pwCF than in controls.

The adjusted ORs for being a prevalent user of AA at year 2 compared to the pre-ETI period was 11.9 (95% CI 1.8-77.0; p=0.009) for pwCF. However, this effect was not significantly different in pwCF than in controls (p=0.090).

Conclusion

We found an increase in use of SPM in pwCF after ETI initiation that was significantly higher than in the background population, strengthening the suspicion of a causal relationship between ETI and sleep disturbances. We also found an increase in use of AA in pwCF, but a similar increase was seen in the background population.

查看原文本刊更多论文

ws01.02囊性纤维化患者在使用elexaftor /tezacaftor/ivacaftor前后睡眠、抑郁和焦虑药物的使用

目的探讨囊性纤维化（pwCF）患者开始使用elexaftor /tezacaftor/ivacaftor （ETI）与睡眠、抑郁和焦虑药物的关系。方法：所有年龄≥12岁的pwCF患者均于2020年8月21日至2021年12月31日在丹麦接受ETI治疗，并在干预前后进行了为期两年的随访。从普通人群中选出的对照组按年龄和性别1:10匹配。结果是流行的使用者状态，定义为在过去一年中至少有一个睡眠促进药（SPM）和2)抗抑郁药和/或抗焦虑药（AA）的赎回处方。处方是从丹麦国家处方登记处获得的，该登记处记录了所有赎回的处方，无论处方医生如何。结果的优势比（or）是根据年龄和COVID封锁天数调整的广义线性混合模型得出的。结果286例pwCF纳入研究。在启动ETI前一年，5.2%的pwCF是SPM的普遍使用者，在启动ETI后的第二年增加到9.0%。相反，使用AA的pwCF从4.9%增加到8.1%。与前eti时期相比，在第2年成为SPM的普遍使用者的调整or为10.9 (95% CI 2.1-55.2；p=0.004)， pwCF患者在第2年的患病几率明显高于对照组（p=0.014）。与eti前相比，在第2年成为AA普遍使用者的调整or为11.9 (95% CI 1.8-77.0；p=0.009)。然而，与对照组相比，pwCF组的这种效应没有显著差异（p=0.090）。结论：我们发现，在ETI开始后，pwCF中SPM的使用明显高于背景人群，这加强了ETI与睡眠障碍之间因果关系的怀疑。我们还发现，在pwCF中AA的使用有所增加，但在背景人群中也有类似的增加。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Cystic Fibrosis 医学-呼吸系统

CiteScore

10.10

自引率

13.50%

发文量

1361

审稿时长

50 days

期刊介绍： The Journal of Cystic Fibrosis is the official journal of the European Cystic Fibrosis Society. The journal is devoted to promoting the research and treatment of cystic fibrosis. To this end the journal publishes original scientific articles, editorials, case reports, short communications and other information relevant to cystic fibrosis. The journal also publishes news and articles concerning the activities and policies of the ECFS as well as those of other societies related the ECFS.